Discovery of IDO1 inhibitors: from bench to bedside
Small-molecule inhibitors of indoleamine 2, 3-dioxygenase-1 (IDO1) are emerging at the
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
Indoleamine 2, 3-dioxygenase and its therapeutic inhibition in cancer
The tryptophan catabolic enzyme indoleamine 2, 3-dioxygenase-1 (IDO1) has attracted
enormous attention in driving cancer immunosuppression, neovascularization, and …
enormous attention in driving cancer immunosuppression, neovascularization, and …
Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses
Indoleamine-2, 3-dioxygenase (IDO) 1 and IDO2 are two closely related tryptophan
catabolizing enzymes encoded by linked genes. The IDO pathway is also …
catabolizing enzymes encoded by linked genes. The IDO pathway is also …
Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive 'cold'tumors 'hot'
We discuss how small-molecule inhibitors of the tryptophan (Trp) catabolic enzyme
indoleamine 2, 3-dioxygenase (IDO) represent a vanguard of new immunometabolic …
indoleamine 2, 3-dioxygenase (IDO) represent a vanguard of new immunometabolic …
Inflammation in cancer and depression: a starring role for the kynurenine pathway
L Sforzini, MA Nettis, V Mondelli, CM Pariante - Psychopharmacology, 2019 - Springer
Depression is a common comorbidity in cancer cases, but this is not only due to the
emotional distress of having a life-threatening disease. A common biological mechanism …
emotional distress of having a life-threatening disease. A common biological mechanism …
Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer
E Fox, T Oliver, M Rowe, S Thomas, Y Zakharia… - Frontiers in …, 2018 - frontiersin.org
Exploding interest in immunometabolism as a source of new cancer therapeutics has been
driven in large part by studies of tryptophan catabolism mediated by IDO/TDO enzymes. A …
driven in large part by studies of tryptophan catabolism mediated by IDO/TDO enzymes. A …
Indoleamine and tryptophan 2, 3-dioxygenases as important future therapeutic targets
Conversion of tryptophan to N-formylkynurenine is the first and rate-limiting step of the
tryptophan metabolic pathway (ie, the kynurenine pathway). This conversion is catalyzed by …
tryptophan metabolic pathway (ie, the kynurenine pathway). This conversion is catalyzed by …
Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo …
In this study, a successful medicinal chemistry campaign that exploited virtual, biophysical,
and biological investigations led to the identification of a novel class of IDO1 inhibitors …
and biological investigations led to the identification of a novel class of IDO1 inhibitors …
[HTML][HTML] Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
A model of the development and progression of chronic fatigue syndrome (myalgic
encephalomyelitis), the aetiology of which is currently unknown, is put forward, starting with …
encephalomyelitis), the aetiology of which is currently unknown, is put forward, starting with …
Amino acid metabolism in rheumatoid arthritis: friend or foe?
In mammals, amino acid metabolism has evolved to act as a critical regulator of innate and
adaptive immune responses. Rheumatoid arthritis (RA) is the most common form of …
adaptive immune responses. Rheumatoid arthritis (RA) is the most common form of …